Highlights
About
DermaBio delivers AI-based precision medicine via skin biomarkers and predictive modeling.
The Future of Precision Medicine Starts with Your Skin
Today, prescribing biologic drugs is a costly guessing game — one that’s growing rapidly as biologics are set to become the standard of care across many diseases. Trial and error treatment leads to wasted time, poor outcomes, and skyrocketing healthcare costs. DermaBio is changing this.
Our AI-powered precision medicine platform combines skin biomarker analysis, a proprietary clinical assay, and advanced data modeling to predict response to biologic therapies. This empowers smarter, faster, and more cost-effective care across multiple diseases.
Our data driven platform combines clinical assays and advanced data modeling to predict response from skin biomarker analysis. Our non-invasive skin swab integrates seamlessly into clinical workflows—fast, painless, and patient-friendly. Clinicians and payers get actionable data.
In short: One versatile platform. A win for clinicians, patients and payers.
Identity
| Name | DermaBio |
|---|---|
| Slug | dermabio |
| Type / kind | startup |
| Source _id | QgCyu0cupevsdSZvFdis72dyOgETTdDUEo0oOnRBWRZmRknCAn3CGm |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Jerusalem District |
| HQ city | Jerusalem |
| HQ address | Jerusalem, Israel |
Web & social
| Website | https://dermab.io |
|---|---|
| https://www.linkedin.com/company/86826650 |
Classifications
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}